Teresa M. Leezer, CEO
Teresa is a global strategist and innovative leader with more than twenty years of Fortune 100 management experience translating to $10 Billion in medical product sales and $250 Million in biomedical startup value. She has secured over $20 Million in development capital from venture, federal and angel financings for early therapeutic, novel biologic and first in class medical device technology startups.
Her management, marketing and global branding expertise encompasses all aspects of company, portfolio and product innovation. As an international launch leader, she is a proven global strategist with keen management skills that drive the creation of new technologies, products and resources to benefit the global community.
In leading diverse teams, Teresa builds consensus and unites efforts around a common goal and vision. She leverages her experience from Hoffman-LaRoche, Merck Labs and Bristol Myers Squibb, as well as her entrepreneurial skills in the creation, management and development of innovative companies, transformational therapies, novel devices, and breakthrough solutions to increase quality of life for patients and their families.
Teresa has managed every phase of the Product Life Cycle: Pre-Clinical, IND Enabling, Clinical Trial Development, Launch, Growth and Maturity. Her Strategic Branding, Marketing, Sales and Management expertise spans the institutional, physician and over the counter markets. Global product launch sales include worldwide blockbusters Fosamax, Zantac, Reyataz, Sustiva, Aleve and Rocephin. Biotechnology startups include RhinoCyte, Inc. and Alltranz/Zynerba Pharmaceuticals ($275 Million IPO/ NASDAQ).
Teresa’s category experience includes: neurology, genomics, regenerative osteoporosis, oncology, virology, anti-infectives, anti-fungals, rheumatology, anesthesiology, dermatology, cardiovascular, pain management, gastroenterology, and immunology.
She has directed significant co-marketing initiatives including the first pharmaceutical product co-promotion in Zantac ($4 billion in global sales) with Roche and Glaxo Smith Kline. Teresa led the co-promotion of Fosamax ($4 billion in global sales) with Merck and Wyeth-Ayerst. She has directed contract sales organizations in the co-promotion of market leaders Flonase ($900 Million) and the first direct to consumer product launch of Aleve ($350 Million).
Teresa has served on numerous community, nonprofit and company boards including RhinoCyte and AllTranz/Zynerba from 2007 to 2015 preparing Zynerba ($275 Million) for an IPO listing on the NSADAQ.